Konstantinos Tziomalos, Asterios Karagiannis and Vasilios G. Athyros Pages 6306 - 6313 ( 8 )
In addition to the modification of the lipid profile, most lipid-lowering agents appear to modulate other atherogenic pathways. We summarize the effects of lipid-lowering agents on inflammation, hemostasis and blood pressure. We also discuss the potential contribution of these actions on cardiovascular disease prevention. Most lipid-lowering agents appear to exert anti-inflammatory, antithrombotic and antihypertensive effects. These pleiotropic actions appear to contribute to the reduction in cardiovascular events and deep venous thrombosis during statin treatment. Regarding other lipid-lowering agents, it is unclear whether their effects on inflammation, thrombosis or blood pressure play a role in their antiatherogenic potential.
Statins, fibrates, ezetimibe, colesevelam, nicotinic acid, C-reactive protein, fibrinogen, blood pressure, pleiotropic effects.
Aristotle University, First Propedeutic Department of Internal Medicine, AHEPA Hospital, 1 Stilponos Kyriakidi street, 546 36, Thessaloniki, Greece.